上海坦蒂生物医药科技

Shanghai Tandi Biomedical Technology (Tandi Bio) is an innovative biopharmaceutical company dedicated to the discovery and development of targeted protein degradation (TPD) drugs. Established in 2021 in Shanghai, the company utilizes its advanced platform to create small molecule degraders, including PROTACs and molecular glues, targeting oncogenic proteins that are difficult to inhibit with traditional methods. Tandi Bio's research is primarily centered on oncology, with a pipeline of early-stage programs aimed at providing novel treatment options for cancer patients. Backed by leading venture capital firms such as Sequoia China and Matrix Partners China, the company is rapidly advancing its technological capabilities and therapeutic candidates. By focusing on the degradation of disease-causing proteins rather than simple inhibition, Tandi Bio aims to overcome resistance mechanisms common in traditional cancer therapies.